BL
LRMR icon

BFSG LLC’s Larimar Therapeutics LRMR Stock Holding History

BFSG LLC’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,000
Closed -$7.74K – 696
2024
Q4 		$7.74K Hold
2,000
– – ﹤0.01% 524
2024
Q3 		$13.1K Hold
2,000
– – ﹤0.01% 476
2024
Q2 		$14.5K Hold
2,000
– – ﹤0.01% 448
2024
Q1 		$15.2K Hold
2,000
– – ﹤0.01% 456
2023
Q4 		$9.1K Buy
+2,000
New +$6.75K ﹤0.01% 464

Other funds holding LRMR

Deerfield Management
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BFSG LLC's LRMR Position: Q1 2025 in Review

BFSG LLC sold out of Larimar Therapeutics (LRMR) in Q1 2025, closing a stake of 2,000 shares — an estimated $7.74K sold.

BFSG LLC first reported a position in LRMR in Q4 2023 and held it in 5 quarters. The position peaked at $15.2K in Q1 2024. 103 funds tracked by Wall St. Rank hold LRMR as of Q1 2025.

  • BFSG LLC reported no remaining Larimar Therapeutics position as of Q1 2025 after selling out during the quarter.
  • BFSG LLC sold 2,000 Larimar Therapeutics shares in Q1 2025, an estimated $7.74K.
  • BFSG LLC first reported a position in Larimar Therapeutics in Q4 2023 and held it in 5 quarters.
  • BFSG LLC's Larimar Therapeutics position peaked at $15.2K in Q1 2024.
  • 103 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2025.

Based on BFSG LLC's 13F filing for Q1 2025, filed 18 Apr 2025.